Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for SCM Lifescience Co., Ltd. (298060:KRX), powered by AI.
SCM Lifescience Co., Ltd. is currently trading at ₩2,890. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for SCM Lifescience Co., Ltd. on Alpha Lenz.
SCM Lifescience Co., Ltd.'s P/E ratio is 126.2.
“SCM Lifescience Co., Ltd. trades at a P/E of 126.2 (premium valuation) with modest ROE of 0.8%. 3Y revenue CAGR of 291.9% highlights clear growth momentum.”
Ask for details →SCM Lifescience Co., Ltd. is a biotechnology company primarily engaged in the research and development of advanced stem cell therapies. The company's specialized focus is on producing high-quality stem cells for therapeutic applications, aiming to address various complex medical conditions. SCM Lifescience operates within the healthcare sector, significantly impacting regenerative medicine and advancing scientific research. By leveraging innovative technologies and proprietary processes, the company is at the forefront of developing cutting-edge treatments that hold immense potential for improving patient outcomes and expanding the horizons of current medical possibilities. SCM Lifescience plays a critical role in pioneering procedures that may transform how diseases are treated in the future, thereby maintaining its importance in the biotech industry. The company's contributions are vital in strengthening the synergy between scientific advancements and practical healthcare solutions, furthering the goals of precision medicine.
“SCM Lifescience Co., Ltd. trades at a P/E of 126.2 (premium valuation) with modest ROE of 0.8%. 3Y revenue CAGR of 291.9% highlights clear growth momentum.”
Ask for details →SCM Lifescience Co., Ltd. (ticker: 298060) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $25.5B.
The current price is ₩2,890 with a P/E ratio of 126.17x and P/B of 0.71x.
ROE is 0.81% and operating margin is -19.00%. Annual revenue is $23.8B.